| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers
| FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY |
| 2023 | Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
| 2022 | The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma
| CLINICAL AND TRANSLATIONAL MEDICINE |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor
| YONSEI MEDICAL JOURNAL |
| 2022 | Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer | CANCER RESEARCH |
| 2022 | Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC | CANCER DISCOVERY |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2021 | Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma | CLINICAL CANCER RESEARCH |
| 2021 | PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15 | CELLULAR & MOLECULAR IMMUNOLOGY |
| 2021 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma | JOURNAL OF HEPATOLOGY |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2020 | Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection | ANNALS OF SURGICAL ONCOLOGY |
